CLINICAL TRIALS PROFILE FOR DESVENLAFAXINE

All Clinical Trials for desvenlafaxine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00256685 ↗	Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2004-09-01	The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators.
NCT00277823 ↗	Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-02-01	The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
NCT00283842 ↗	Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy	Terminated	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-03-01	The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
NCT00300378 ↗	Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-03-01	The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder. Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.
NCT00329147 ↗	Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-05-01	The purpose of this study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
NCT00329186 ↗	Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-05-01	The purpose of this study is to determine if the relative difference in PK between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.

Clinical Trial Conditions for desvenlafaxine

Condition Name

Condition Name for desvenlafaxine
Intervention	Trials
Major Depressive Disorder	27
Depressive Disorder, Major	9
Depression	8
Vasomotor Symptoms	6

Condition MeSH

Condition MeSH for desvenlafaxine
Intervention	Trials
Depression	46
Depressive Disorder	45
Depressive Disorder, Major	42
Disease	24

Clinical Trial Locations for desvenlafaxine

Trials by Country

Trials by Country for desvenlafaxine
Location	Trials
United States	499
Canada	31
Japan	21
Mexico	9
South Africa	7

Trials by US State

Trials by US State for desvenlafaxine
Location	Trials
Florida	26
Ohio	23
California	22
Texas	20
Georgia	19

Clinical Trial Progress for desvenlafaxine

Clinical Trial Phase

Clinical Trial Phase for desvenlafaxine
Clinical Trial Phase	Trials
Phase 4	17
Phase 3	30
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for desvenlafaxine
Clinical Trial Phase	Trials
Completed	55
Unknown status	6
Terminated	6

Clinical Trial Sponsors for desvenlafaxine

Sponsor Name

Sponsor Name for desvenlafaxine
Sponsor	Trials
Pfizer	27
Wyeth is now a wholly owned subsidiary of Pfizer	25
Luye Pharma Group Ltd.	4

Sponsor Type

Sponsor Type for desvenlafaxine
Sponsor	Trials
Industry	61
Other	38